Crucell, DSM Biologics announce PER.C6 licensing agreement with UMN Pharma

By E. Janene Geiss

Philadelphia, March 9 - Crucell NV and allied contract manufacturer DSM Biologics announced Thursday that they have signed a PER.C6 research license agreement with Japanese pharmaceutical company UMN Pharma.

The agreement allows UMN Pharma to use the PER.C6 cell line in its "UMN-03" project, which aims to employ a fusion protein in the treatment of muscular dystrophy and metabolic diseases such as obesity and type 2 diabetes mellitus, according to a company news release.

In addition, Crucell and DSM Biologics said they will provide UMN Pharma with various services including vector construction, clone generation, process development and cGMP manufacturing, through its own facilities in Groningen, The Netherlands and within the PER.C6 vendor network.

Under the agreement, UMN Pharma will pay a signing fee and annual maintenance fees. Additional services also will attract fees, officials said. Further financial details were not disclosed.

Crucell is a Leiden, The Netherlands, biotechnology company focused on research, development, production and worldwide marketing of vaccines and antibodies that combat infectious diseases.

DSM Biologics, a business unit of DSM Pharmaceutical Products based in Montreal, is a provider of manufacturing technology and services to the biopharmaceutical industry.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.